Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DKM-412
- Development stage
- Unknown
- Lead developer
- Dongkook Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intraarticular
01
Overview
DKM-412 is an incrementally modified drug (IMD) developed by Dongkook Pharma for the treatment of knee osteoarthritis. It is designed as a sustained-release intra-articular injection, likely utilizing microsphere technology to extend the therapeutic effect of its active ingredient, triamcinolone acetonide. As a corticosteroid, triamcinolone acetonide functions as a glucocorticoid receptor agonist, exerting potent anti-inflammatory and analgesic effects within the synovial space. The sustained-release profile of DKM-412 is intended to provide prolonged relief from the symptoms of osteoarthritis, potentially reducing the frequency of injections required for patient management compared to standard immediate-release corticosteroid formulations.
02
Targets
GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on DKM-412.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DKM-412.